HER2-positivity rates in advanced gastric cancer (GC): Results from a large international phase III trial

Bang, Y.; Chung, HC; Sawaki, Akira; Xu, Jing; Lin, Senjie; Липатов, О. Н.; Park, S. R.; Gangadharan, V P; Advani, Suresh H.; Kang, Yubin

doi:10.1200/jco.2008.26.15_suppl.4526

Cited by 12 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An HER-2 overexpression was observed in 30% of the patients in our study and is in accordance with previously reported results (3,4), ranging from 6 to 35% of patients with gastroesophageal adenocarcinoma (Table II). For GC, HER-2 positivity was detected in 15 (32%) of the 47 patients.…”

Section: Discussionsupporting

confidence: 95%

“…Only patients exhibiting overexpression of the HER-2 protein, as defined by an immunohistochemistry (IHC) score of 2+ and HER-2 gene amplification with fluorescence in situ hybridization (FISH) or colorimetric in situ hybridization (CISH) and an IHC score of 3+, are considered to be candidates for treatment with trastuzumab. HER-2 overexpression was reported in 6-35% of patients with gastroesophageal adenocarcinoma (3)(4)(5). The differences in HER-2 expression between those trials may be explained by the differences in methodology and sample size in the respective series.…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract

Hejna

Birner

Preusser

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

The assessment of the human epidermal growth factor receptor-2 (HER-2) status has become a routine diagnostic procedure for patients with advanced-stage gastroesophageal adenocarcinoma. The aim of this study was to evaluate the possible correlation between the HER-2 status and the ABO blood group. HER-2 status determination and routine ABO typing was performed according to current standards. We evaluated the correlation between the HER-2 status and the ABO and Rhesus (Rh) system in 100 consecutive patients with adenocarcinoma of the upper gastrointestinal tract. There were no significant differences between HER-2 status and ABO and Rh system. Furthermore, no correlation was observed between the HER-2 status and the ABO and Rh type in patients with adenocarcinoma of the upper gastrointestinal tract.

show abstract

Section: Discussionsupporting

confidence: 95%

Section: Introductionmentioning

confidence: 97%

Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract

Hejna

Birner

Preusser

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Our study, which examined a cohort composed of more than 90% GE junction adenocarcinomas, agrees with the largest study that performed immunohistochemical studies and FISH and found 32% of GE junction adenocarcinomas positive for HER2 amplification. 20 …”

Section: Discussionmentioning

confidence: 99%

HER2Amplification in Gastroesophageal Adenocarcinoma

et al. 2012

View full text Add to dashboard Cite

We assessed 103 resected gastroesophageal adenocarcinomas for HER2 amplification by fluorescence in situ hybridization (FISH) and 2 commercial immunohistochemical assays. Of 103, 30 (29%) were FISH-amplified. Both immunohistochemical assays had greater than 95% concordance with FISH. However, as a screening test for FISH amplification, the Ventana Medical Systems (Tucson, AZ) 4B5 antibody demonstrated superior sensitivity (87%) compared with the DAKO (Carpinteria, CA) A0485 (70%). Of the cases, 28 were immunohistochemically 3+ or immunohistochemically 2+/FISH-amplified with the 4B5 assay compared with only 22 cases with the A0485 assay, representing a large potential difference in patient eligibility for anti-HER2 therapy. Cases with low-level FISH amplification (HER2/CEP17, 2.2–4.0) express lower levels of HER2 protein compared with cases with high-level amplification (HER2/CEP17, ≥4.0), raising the possibility of a differential response to anti-HER2 therapy. The H score and digital image analysis may have a limited role in improving HER2 test performance.

show abstract

“…In addition, differences between HER2 overexpression in European and Asian/South-American populations (22–28% versus 3–15%, resp.) have been reported by some studies [68], but others have found these differences to be less substantial [69]. The largest data set of >3,800 advanced esophageal and gastric cancer samples found HER2 protein positivity rates of 23% [57, 68].…”

Section: Human Epidermal Growth Factor Receptormentioning

confidence: 98%

HER-2/neuTesting and Therapy in Gastroesophageal Adenocarcinoma

Moelans

Diest

Milne

et al. 2011

Pathology Research International

View full text Add to dashboard Cite

Despite ongoing advances in the treatment of gastroesophageal cancer, prognosis remains poor. The best promise to improve this poor survival is provided by new targeted agents. Of these, human epidermal growth factor receptor 2 (HER2) is currently in the spotlight. In this review, we provide an overview of recent developments in HER2 testing and results of clinical trials targeting HER2 in gastroesophageal adenocarcinoma. Based on the encouraging ToGA trial findings it is now expected that routine HER2 testing will be included in the diagnostic work-up of patients with advanced gastric cancer. With regard to this testing, overexpression of the HER2 protein seems to possess the best predictive properties. However, HER2 immunohistochemistry (IHC) is subject to assay and interobserver variability, so standardization and internal and external proficiency testing is an absolute prerequisite, especially as the IHC scoring system in gastric cancer is different from that of breast cancer. Further study is needed to investigate the clinical meaning of the significant heterogeneity observed in both gene amplification and protein overexpression in gastroesophageal cancer. Highly effective therapies for gastroesophageal cancer can only be accomplished by a multi-targeted approach, considering crosstalk between pathways and continuing to optimize chemotherapy.

show abstract

HER2-positivity rates in advanced gastric cancer (GC): Results from a large international phase III trial

Cited by 12 publications

References 0 publications

Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract

Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract

HER2Amplification in Gastroesophageal Adenocarcinoma

HER-2/neuTesting and Therapy in Gastroesophageal Adenocarcinoma

Contact Info

Product

Resources

About